FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022605737> ?p ?o ?g. }

• W2022605737 endingPage "300" @default.
• W2022605737 startingPage "300" @default.
• W2022605737 abstract "To the Editor: Smoldering multiple myeloma (SMM) is a premalignant plasma cell proliferative disorder defined by a serum M protein (SMP) of 3 g/dL or higher and/or 10% or greater of bone marrow plasma cells (BMPC), without end-organ damage.1International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.Br J Haematol. 2003; 121: 749-757Crossref PubMed Scopus (1960) Google Scholar The clinical course and prognosis of 276 patients diagnosed as having SMM between 1970 and 1995 have been reported.2Kyle RA Remstein ED Therneau TM et al.Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.N Engl J Med. 2007; 356: 2582-2590Crossref PubMed Scopus (627) Google Scholar At initial diagnosis, a risk stratification model divided patients into group 1 (BMPC ≥10%, SMP ≥3 g/dL), group 2 (BMPC ≥10%, SMP <3 g/dL), and group 3 (BMPC <10%, SMP ≥3 g/dL), which resulted in a median time to progression of 2, 8, and 19 years, respectively. The study identified BMPC percent and the SMP level at diagnosis as the 2 independent risk factors for progression.2Kyle RA Remstein ED Therneau TM et al.Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.N Engl J Med. 2007; 356: 2582-2590Crossref PubMed Scopus (627) Google Scholar The study analyzed various baseline factors with respect to progression of SMM, but plasma cell labeling index (PCLI) was not evaluated because it was not routinely performed until the slide-based immunofluorescence method3Greipp PR Kumar S Plasma cell labeling index.Methods Mol Med. 2005; 113: 25-35PubMed Google Scholar became available in 1984. The PCLI is a powerful and independent predictor of survival in patients with newly diagnosed multiple myeloma because it provides a measure of the proliferative rate of the malignant BMPC.4Greipp PR Lust JA O'Fallon WM Katzmann JA Witzig TE Kyle RA Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.Blood. 1993; 81: 3382-3387PubMed Google Scholar Additionally, the incorporation of PCLI into the international staging system of multiple myeloma provides prognostic value for stage 1 and 2 patients.5Kapoor P Snozek C Colby CL et al.Incorporation of the plasma cell labeling index into the international staging system of multiple myeloma: impact on prognostic value [abstract 8591].J Clin Oncol. 2008; 26: 15SGoogle Scholar We conducted this study to determine if the baseline PCLI would be a risk factor for progression of SMM. Of the 175 patients diagnosed as having SMM after January 1, 1984, 161 (92%) had PCLI at diagnosis, and these patients form the study group. The progression rates were estimated using the Kaplan-Meier method. Among the 68 patients in group 1, progression occurred in 44 of 63 with PCLI lower than 1 and 4 of 5 with PCLI of 1 or greater. The 2- and 5-year rates of progression were 40.4% (95% confidence interval [CI], 26.4%-51.7%) and 68.4% (95% CI, 52.8%-78.9%) (PCLI <1) compared with 60.0% (95% CI, 0%-86.3%) and 80.0% (95% CI, 0%-96.3%) (PCLI ≥1) (P=.4). Among the 83 patients in group 2, progression occurred in 42 of 79 with PCLI lower than 1 and all 4 patients with PCLI of 1 or greater. The 2- and 5-year rates of progression were 21.2% (95% CI, 11.0%-30.1%) and 43.1% (95% CI, 29.7%-54.0%) (PCLI <1) compared with 75.0% (95% CI, 0%-95.4%) and 100% (PCLI ≥1) (P<.001). No analysis could be performed for group 3 because all 10 patients had PCLI lower than 1. Overall, the median time to progression was 1.2 years (PCLI ≥1) and 2.6 years (PCLI <1) (P<.001) (Figure). At 1 year after diagnosis of SMM, progression occurred more than twice as frequently in patients with PCLI of 1 or greater (50%) than in those with PCLI lower than 1 (23%). In conclusion, SMM patients with BMPC of 10% or greater and PCLI of 1 or greater had higher rates of progression, but because of a small number of patients with PCLI of 1 or greater, a statistical significance occurred only in group 2. Our study demonstrates the usefulness of PCLI as a risk factor for progression of SMM, especially among those with BMPC of10% or greater and SMP lower than 3 g/dL. Along with other risk factors, it can be used to further stratify SMM patients as a guide in the design of clinical trials and follow-up and to ensure timely institution of effective therapy before organ impairment develops. The main limitation of PCLI is that the test is not widely available. Other methods to estimate the proliferative rate, such as flow cytometric assessment of the percentage of S-phase plasma cells or gene expression profiling, may be equally good alternatives and should be studied." @default.
• W2022605737 created "2016-06-24" @default.
• W2022605737 creator A5023193953 @default.
• W2022605737 creator A5072775789 @default.
• W2022605737 creator A5090087547 @default.
• W2022605737 date "2010-03-01" @default.
• W2022605737 modified "2023-09-24" @default.
• W2022605737 title "Plasma Cell Labeling Index in the Evaluation of Smoldering (Asymptomatic) Multiple Myeloma" @default.
• W2022605737 cites W1781784766 @default.
• W2022605737 cites W1974983065 @default.
• W2022605737 cites W2164807675 @default.
• W2022605737 doi "https://doi.org/10.4065/mcp.2009.0653" @default.
• W2022605737 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2843123" @default.
• W2022605737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20194156" @default.
• W2022605737 hasPublicationYear "2010" @default.
• W2022605737 type Work @default.
• W2022605737 sameAs 2022605737 @default.
• W2022605737 citedByCount "19" @default.
• W2022605737 countsByYear W20226057372012 @default.
• W2022605737 countsByYear W20226057372013 @default.
• W2022605737 countsByYear W20226057372014 @default.
• W2022605737 countsByYear W20226057372015 @default.
• W2022605737 countsByYear W20226057372016 @default.
• W2022605737 countsByYear W20226057372017 @default.
• W2022605737 countsByYear W20226057372018 @default.
• W2022605737 countsByYear W20226057372019 @default.
• W2022605737 countsByYear W20226057372020 @default.
• W2022605737 countsByYear W20226057372021 @default.
• W2022605737 crossrefType "journal-article" @default.
• W2022605737 hasAuthorship W2022605737A5023193953 @default.
• W2022605737 hasAuthorship W2022605737A5072775789 @default.
• W2022605737 hasAuthorship W2022605737A5090087547 @default.
• W2022605737 hasBestOaLocation W20226057371 @default.
• W2022605737 hasConcept C126322002 @default.
• W2022605737 hasConcept C143998085 @default.
• W2022605737 hasConcept C2776364478 @default.
• W2022605737 hasConcept C2776396001 @default.
• W2022605737 hasConcept C2777910003 @default.
• W2022605737 hasConcept C71924100 @default.
• W2022605737 hasConcept C90924648 @default.
• W2022605737 hasConceptScore W2022605737C126322002 @default.
• W2022605737 hasConceptScore W2022605737C143998085 @default.
• W2022605737 hasConceptScore W2022605737C2776364478 @default.
• W2022605737 hasConceptScore W2022605737C2776396001 @default.
• W2022605737 hasConceptScore W2022605737C2777910003 @default.
• W2022605737 hasConceptScore W2022605737C71924100 @default.
• W2022605737 hasConceptScore W2022605737C90924648 @default.
• W2022605737 hasIssue "3" @default.
• W2022605737 hasLocation W20226057371 @default.
• W2022605737 hasLocation W20226057372 @default.
• W2022605737 hasLocation W20226057373 @default.
• W2022605737 hasLocation W20226057374 @default.
• W2022605737 hasOpenAccess W2022605737 @default.
• W2022605737 hasPrimaryLocation W20226057371 @default.
• W2022605737 hasRelatedWork W129423339 @default.
• W2022605737 hasRelatedWork W1987215768 @default.
• W2022605737 hasRelatedWork W1991129960 @default.
• W2022605737 hasRelatedWork W1995188757 @default.
• W2022605737 hasRelatedWork W2016679923 @default.
• W2022605737 hasRelatedWork W2116001782 @default.
• W2022605737 hasRelatedWork W2131457795 @default.
• W2022605737 hasRelatedWork W2943195325 @default.
• W2022605737 hasRelatedWork W4229900919 @default.
• W2022605737 hasRelatedWork W17604275 @default.
• W2022605737 hasVolume "85" @default.
• W2022605737 isParatext "false" @default.
• W2022605737 isRetracted "false" @default.
• W2022605737 magId "2022605737" @default.
• W2022605737 workType "article" @default.